Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 4
Submit an article Journal homepage
5
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Patent Update Central & Peripheral Nervous System: Recent advances in opioid and non-opioid analgesia (1992–1993)

Jeffery B Press RW Johnson Pharmaceutical Research Institute, Welsh & McKean Roads, Spring House, Pennsylvania, PA, 19477-0776, USA Johnson Pharm Res Ins, Welsh & McKean Rds, Spring House, Pennsylvania, PA, 19477-0776 USA
&
Robert B Raffa RW Johnson Pharmaceutical Research Institute, Welsh & McKean Roads, Spring House, Pennsylvania, PA, 19477-0776, USA Johnson Pharm Res Ins, Welsh & McKean Rds, Spring House, Pennsylvania, PA, 19477-0776 USA
Pages 379-393 | Published online: 03 Mar 2008

References to Primarv Literaturess

  • FRANZ DN: Review of research on receptor pharmacol-ogy of pain and analgesia: part one. APS Bull. (1993) 3:10–13.
  • TRAYNOR JR, Einarr j: 8 -Opioid receptor subtypes andcross-talk with is-receptors. Trends Pharmacol. Sci. (1993) 14:84–86.
  • JIANG W, MOSBERG HI, PORRECA F: Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. j Pharmacol. Exp. Ther. (1990) 254:683–689.
  • LIPP J: Review - Possible mechanisms of morphine analgesia. Clin. Neuropharmacol. (1991) 14:131–147.
  • RAFFA RB, MARTINEZ RP: Morphine antinociception is mediated through a LiCi-sensitive, 1P3-restorable path-way. Eur. J. Pharmacol. (1992) 215:357–358.
  • WILD KD, MCCORMICK J, BILSKY EJ, VANDERAH T, MCNUTT RW, CHANG K-J, PORRECA F: Antinociceptive actions of 5W373U86 in the mouse. J. Pharmacol. Exp. Ther. (1993), 267:858–867.
  • CHANG K-J, RIDGON GC, HOWARD JL, MCNUTT RW: Anovel, potent and selective nonpeptide delta opioid receptor agonist I3W373U86. J. Pharmacol. Exp. Ther. (1993), 267:852–887.
  • COMER SD, HOENICKE EM, SABLE Al, MCNUTT PW, CHANG K-J, DE COSTA BR, MOSBERG HI, WOODS JH: Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J. Pharmacol. Exp. Ther. (1991) 267:888–895.
  • SOFUOGLU M, PORTOGHESE PS, TAKEMORI AE: Differ-ential antagonism of 8 opioid agonists by naltrindole and its benzofuran analogue (NTB) in mice: evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. (1991) 257:676–680.
  • SOFUOGLU M, PORTOGHESE PS, TAKEMORI AE: Cross- tolerance studies in the spinal cord of I3-FNA-treated mice provides further evidence for delta opioid recep-tor subtypes. Life Sci/Pharmacol. Letts. (1991) 49:PL153-PL156.
  • JIANG Q, TAKEMORI AE, SULTANA M, PORTOGHESE PS, BOWEN WD, MOSBERG HI, PORRECA F: Differential antagonism of opioid delta antinociception by [D-ma2,Leus,cys6kiikephalin and naltrindole 5'-isothlocy-anate: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. (1991) 257:1069–1075.
  • MATITA A, VANDERAH T, MOSBERG HI, PORRECA F: lack
  • EVANS CJ, KEITH DE JR, MORISSON H, MAGENDZO K, EDWARDS RH: Cloning of a delta opioid receptor by functional expression. Science (1992) 258:1952–1955.
  • KIEFFER BL, BERFORT K, GAVERIAUX-RUFF C, HIRTH CG: The 8-opiold receptor: isolation of a cDNA by expres-
  • WOLOZIN BL, PASTERNAK GW: Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. USA (1981) 78:6181–6185.
  • LING GSF, SPIEGEL K, LOCKHART SH, PASTERNAK GW: Separation of opioid analgesia from respiratory depres-sion: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther. (1985) 232:149–155.
  • LING GSF, SPIEGEL K, NISHIMURA SL, PASTERNAK GW: Dissociation of morphine's analgesic and respiratory depressant actions. Eur. J. Pharmacol. (1983) 86:487–488.
  • PAUL D, PASTERNAK GW: Differential blockade by naloxonazine of two µ opiate actions: analgesia and Inhibition of gastrointestinal propulsion in the mouse: studies with naloxonazine. J. Pharmacol. Exp. Ther. (1988) 149:403–404.
  • HEYMAN JS, WILLIAMS CL, BURRS TF, MOSBERG HI, POR-RECA F: Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: stud-ies with naloxonazine. j Pharmacol. Exp. Ther. (1988) 245:238–243.
  • LING GSF, MACLEOD JM, LEE S, LOCKHART SH, PASTER-NAK GW: Separation of morphine analgesia from physi-cal dependence. Science (1984) 226:462–464.
  • ROQUES BP, FOURNIE-ZALUSKI M-C, SOROCA E, LE-COMTE J-M, MALFROY B, LLORENS C, SCHWARTZ J-C: The enkephalinase inhibitor thiorphan shows antinocicep-tive activity in mice. Nature (London) (1980) 288:286–288.
  • LECOMTE J-M, COSTENTIN j, VLAICUIESCII A, CHAILLET P, MARCAIS-COLLADO H, LLORENS-CORTES C, LEBOYER M, SCHWARTZ J-C: Pharmacological properties of acetrophan, a parentally active `enckephalismse' inhibi-tor. J. Pharmacol. Exp. Ther. (1986) 237:937–944.
  • CHIPKIN RE, LATRANYI MB, McCHUGH D: SCH34826, an enkephalinase inhibitor analgesic, does not produce tolerance or dependence in rats. Adv. Biosci. (1989) 75:763–766.
  • MALDONADO R, FEGER J, FOURNIE-ZALUSKI M-C, RO- QUES BP: Differences in physical dependence induced by selective 11 and 5 opioid agonists and by endogenotes enkephalins protected by peptidase inhibitors. Br. Res. (1990) 520:247–254.
  • NOBLE F, TURCAUD 5, FOURNIE-ZALUSKI M-C, ROQUESBP: Repeated systemic administration of the mixed Inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. Eur.J. Pharmacol. (1992) 223:83–89.
  • NOBLE F, CORIC P, FOURNIE-ZALUSKI M-C, ROQUES BP:Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin- degrading enzymes, RB101. Eur.J. Phar-macol. (1992) 223:91–96.
  • RAFFA RB, FRIEDRICHS E, REIMANN W, SHANK RP, CODDEE, VAUGHT JL: Opioid and nonopioid components Independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.]. Pharmacol. Exp. Ther. (1992) 260:275–285.
  • RAFFA RB, FRIEDRICHS E, REIMANN W, SHANK RP, CODDEE, VAUGHT JL, JACOBY HI, SELVE N: Complementary and synergistic antinociceptive interaction between the enantiomers of tramadoL J. Pharmacol. Exp. Ther. (1993) 267:331–340.
  • MUSSAP CJ, GERAGHTY DP, BURGHER E: Short Review -Tachyldnin receptors: a radioligand binding perspec-tive. J. Neurochem. (1993) 60:1987–2009.
  • LOWE IIIJA, DROZDA SE, SNIDER RM, LONGO KP, ZORNSH, MORRONE J, JACKSON ER, MCLEAN S, BRYCE DK, BORDNER J, NAGAHISA A, KANAI Y, SUGA 0, TSUGHIYA M: The discovery of (2S3S)cis-2-octan-3-amine as a novel, nonpeptide substance P antagonist.]. Med. Chem. (1992) 35:2591–2600.
  • WATLING KJ: Nonpeptide antagonists herald new era intachykinin research. Trends Pharmacol. Sci (1992) 13:266–269.
  • YAMAMOTO T, YAKSH TL: Stereospecific effects of anonpeptide NICi selective antagonist, CP-96,345: antino-ciception in the absence of motor dysfunction. Life Sci. (1991) 49:1955–1963.
  • KURALSHI Y, HIROTA N, SATO Y, HANASHIMA N, TAKAGIH, SATOH M: Stimulus specificity of peripherally evoked substance P release from the rabbit dorsal born in situ. Neurosci (1989) 30:241–250.
  • KANTNER RM, KIRBY ML, GOLDSTEIN BD: Increase in substance P in the dorsal horn during a chemogenic nociceptive stimulus. Br. Res, (1985) 338:196–199.
  • GUARD S, WATLING KJ: Interaction of the non-peptideNK2 receptor antagonist (±) CP-96,345 with L-type cal-cium channels in rat cerebral cortex. Br. J. Pharmacol. (1992) 106:37P.
  • BARNES PJ, BELVISI MG, ROGERS DF: Modulation ofneurogenic inflammation: novel approaches to inflam-matory disease. Trends Pharmacol. Sci. (1990) 11:185–189.
  • KYLE DJ, BURCH RM: A survey of bradykinin receptorsand their antagonists. Curr. Opin, Invest. Drugs (1993) 2:5–20.
  • FARMER SG, BURCH RM: Biochemical and molecular pharmacology of kinin receptors. Ann. Rev. Pharmacol. Toxicol. (1992) 32:511–536.
  • DRAY A, PERKINS M: Bradykinin and inflammatory pain.Trends Neurasci. (1993) 16:99–104.
  • STERANKA LR: Potential clinical utility of bradykininantagonists. Inernational Kinin Conference, Munich, Ger-many (1991): Abstract p. 108.
  • MORAN TH, ROBINSON PH, GOLDRICH MS, MCHUGH PR:Two brain cholecystokinin receptors: implications for behavioral actions. Br. Res. (1986) 362:175–179.
  • WILLS WD JR, COGGESHALL RE: In: Sensor y Mechanisms of the Spinal Cord(1991). Plenum Press, New York. pp. 134–136.
  • TUCHSCHERER MM, KNOX C, SEYBOLD VS: Substance P and cholecystokinin-like immunoreactive varicosities In somatosensory and autonomic regions of the rat spinal cord: a quantitative study of coexistence. J. Neuro-sci. (1987) 7:3984–3995.
  • ROTHMAN RB: A review of the role of anti-opioid pep-tides in morphine tolerance and dependence. Synapse (1992) 12:129–138.
  • BABER NS, DOURISH CT, HILL DR: Review Article - Therole of CCK, caerulein, and CCK antagonists in nocicep-don. Pain (1989) 39:307–328.
  • DOURISH CT, O'NEILL MF, COUGHLAN J, IUTCHENER SJ,HAWLEY D, IVERSEN SD: The selective CCK-B receptor antagonist 1,365,260 enhances morphine analgesia and prevents morphine tolerance lathe rat. Eur.J. Pharma-col. (1990) 176:35–44.
  • WIESENFELD-HALLIN Z, XU X-J, HUGHES J, HORWELL DC,HOKFELT T: PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analge-sic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive re-flexes. Proc. Natl. Acad. Sci. USA (1990) 87:7105–7109.
  • ABBRUZZESE JL, GHOLSON CF, DAUGHERTY K, LARSONE, DUBROW R, BERLIN R, LEVIN B: A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in pa-tients with advanced pancreatic cancer. Pancreas (1992) 7:165–171.
  • WILLIS WD JR, COGGESHALL RE: In: Sensory Mechanismsof the Spinal Cord (1991). Plenum Press, New York. p. 207.
  • MAX MB, KLSHORE-KUMAR R, SCHAFER SC, MEISTER B,GRACELY RH, SMOLLER B, DUBNER R: Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled triaL Pain (1991) 45:3–9.
  • BARBER A, HARTING J, WOLF H-P: Antinociceptive ef-fects of the 5-HT2 antagonist ritanserin in rats: evidence for an activation of descending monoarculnersk path-ways bathe spinal cord. Neurosci. Letts. (1989)99:234–238.
  • VAN PRAAG H, FRENK H: The role of glutamate in opiate descending inhibition of nociceptive spinal reflexes. Br. Res. (1990) 524:101–105.
  • FRANCE CP, WINGER GD, WOODS J11: Analgesic, anes-thetic, and respiratory effects of the competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys. Br. Res. (1990) 526:355–358.
  • TRUJILLO KA, AKIL H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science (1991) 251:85–87.
  • KLEPSTAD P, MAURSET A, MOBERG ER, ØYE I: Evidenceof a role for NMDA receptors in pain perception. Eur.J. Pharmacol. (1990) 187:513–518.
  • HAUBRICH DR, WARD SJ, BAIZMAN E, BELL MR, BRAD-FORD J, FERRARI R, MILLER M, PERRONE M, PIERSON AK, SAELENS JK, LUTTINGER D: Pharmacology of pravadoline: a new analgesic agent J. Pbarmacol. Exp. Then (1990) 255:511–522.
  • JANSEN EM, HAYCOCK DA, WARD SJ, SEYBOLD VS: Dis-tribution of cannabinoid receptors in rat brain deter-mined with aminoalkylindoles. Br. Res. (1992) 575:93–102.
  • TORAY IND INC, W09315081-A (1993).
  • ROUSSEL-UCLAF, EP-534844-A (1993).
  • DUPONT MERCK PHARM CO, W09212128-A (1992).
  • Dr LO ZAMBELETTI SPA, W09215304-A (1992).
  • Dr LO ZAMBELETTI SPA, W09215592-A (1992).
  • Dr LO ZAMBELETTI SPA, W09217467-A (1992).
  • Dr LO ZAMBELETTI SPA, W09220657-A (1992).
  • GD SEARLE & CO, US5225417-A (1993).
  • GD SEARLE & CO, US5223507-A (1993).
  • Dr LO ZAMBELETTI SPA, W09301186-A (1993).
  • ALKALOIDA CHEM CO, W09213534-A (1993).
  • GLAXO INC, US5130321-A (1992).
  • WELCOME FOUNDATION LTD, '0709315062 (1993).
  • WARNER-LAMBERT CO, EP552386-A (1993).
  • H LUNDEBECK AS, W09222530-A (1992). 116, NISSHIN FLOUR MILLING CO LTD, GB22511435-AS
  • SCHERING CORP, W09211235-A (1992).
  • CIBA-GIEGY CORP, US5217996-A (1993).
  • MERREL DOW PHARM INC, EP-481522-A (1992).
  • ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI, EP- 47553-A (1992).
  • McNEILAB INC, EP-532348-A (1993).
  • McNEILAB INC, EP-546676-A (1993).
  • McNEILAB INC, EP-534628-A (1993).
  • McNEILAB INC, W09304675-A (1993).
  • PFIZER INF, W09300331-A (1993).
  • PFIZER INF, W09300330-A (1993).
  • MERCK SHARP & DOHME LTD, EP-520555-A (1992).
  • MERCK SHARP & DOHME LTD, EP-536817-A (1993).
  • MERCK SHARP & DOHME LTD, EP-528495-A (1993).
  • MERCK SHARP & DOHME LTD, W09301165-A (1993).
  • MERCK SHARP & DOHME LTD, W09301160-A (1993).
  • MERCK SHARP & DOHME LTD, W09301169-A (1993).
  • RHONE-POULENC RORER SA, EP-514274-A (1992).
  • RHONE-POULENC RORER SA, EP-514275-A (1991).
  • RHONE-POULENC RORER SA, EP-514276-A (1991).
  • RHONE-POULENC RORER SA, EP-514273-A (1992).
  • FUJISAWA PHARM CO LTD, US5217952-A (1993).
  • NOVA TECH LTD PARTNERSHIP, W09311789-A (1993).
  • MERCK & CO INC, EP-481671-A (1992).
  • MERCK & CO INC, EP-517412-A (1991).
  • MERCK & CO INC, EP-508796-A (1991).
  • MERCK & CO INC, US5220018-A (1991).
  • MERCK & CO INC, EP-508798-A (1992).
  • MERCK & CO INC, US5220017-A (1992).

References to the patent literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.